Evidence map›Paper›PMID 32296058›Full record

ArticleNature communications2020

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma.

Akash Mitra, Miles C Andrews, Whijae Roh, Marianna Petaccia De Macedo, Courtney W Hudgens, Fernando Carapeto, Shailbala Singh, Alexandre Reuben, Feng Wang, Xizeng Mao and 27 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 4 institutions in 2 countries.

Akash Mitra *Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0002-0633-1615
Miles C Andrews *Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0003-1231-8641
Whijae RohThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.ORCID http://orcid.org/0000-0002-7395-9939
Marianna Petaccia De MacedoDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0002-0434-7605
Courtney W HudgensDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0001-8312-7485
Fernando CarapetoDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Shailbala SinghDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Alexandre ReubenDepartment of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0003-4510-0382
Feng WangDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Xizeng MaoDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Xingzhi SongDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Khalida WaniDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Samantha TippenDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kwok-Shing NgInstitute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0003-0364-7443
Aislyn SchalckDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Donald A Sakellariou-ThompsonDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Eveline ChenDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sangeetha M ReddyDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Christine N SpencerParker Institute for Cancer Immunotherapy, San Francisco, California, USA.
Diana WiesnoskiDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Latasha D LittleDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Curtis GumbsDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Zachary A CooperAstraZeneca, Gaithersburg, Maryland, USA.ORCID http://orcid.org/0000-0003-1059-0940
Elizabeth M BurtonDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Patrick HwuDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Michael A DaviesDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0002-0977-0912
Jianhua ZhangDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0001-5412-9860
Chantale BernatchezDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nicholas NavinDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Padmanee SharmaDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
James P AllisonDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jennifer A WargoDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0003-3438-7576
Cassian YeeDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Michael T TetzlaffDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wen-Jen HwuDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Alexander J LazarDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0002-6395-4499
P Andrew FutrealDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. AFutreal@mdanderson.org.ORCID http://orcid.org/0000-0001-8663-2671
The University of Texas MD Anderson Cancer Center · USAstraZeneca (United States) · USBroad Institute · USParker Institute for Cancer Immunotherapy · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Comprehensive Training Program in Musculoskeletal ResearchT32AR065971 · NIAMS · INDIANA UNIVERSITY INDIANAPOLIS · PI ALEXANDER G ROBLING · 2015 to 2026
$4.4M
NCI NIH HHS P30 CA016672NIAMS NIH HHS T32 AR065971
6 · The paper itself

Abstract

Complex tumor microenvironmental (TME) features influence the outcome of cancer immunotherapy (IO). Here we perform immunogenomic analyses on 67 intratumor sub-regions of a PD-1 inhibitor-resistant melanoma tumor and 2 additional metastases arising over 8 years, to characterize TME interactions. We identify spatially distinct evolution of copy number alterations influencing local immune composition. Sub-regions with chromosome 7 gain display a relative lack of leukocyte infiltrate but evidence of neutrophil activation, recapitulated in The Cancer Genome Atlas (TCGA) samples, and associated with lack of response to IO across three clinical cohorts. Whether neutrophil activation represents cause or consequence of local tumor necrosis requires further study. Analyses of T-cell clonotypes reveal the presence of recurrent priming events manifesting in a dominant T-cell clonotype over many years. Our findings highlight the links between marked levels of genomic and immune heterogeneity within the physical space of a tumor, with implications for biomarker evaluation and immunotherapy response.

Indexed as

Biomarkers, TumorDNA Copy Number VariationsGenomicsHumansMelanomaMutationNeutrophil ActivationTumor MicroenvironmentBiomarkers, Tumor

Identifiers

PMID32296058
PMCPMC7160105
OpenAlexW3016947983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.